SGLT2抑制剂改善常见ALDH2酒精潮红变异相关的内皮功能障碍
常见ALDH2*2酒精潮红变异影响全球约8%人口,与冠状动脉疾病(CAD)风险增加相关。研究通过日本生物样本库GWAS、携带者临床内皮功能评估、人诱导多能干细胞来源内皮细胞(iPSC-ECs)及CRISPR-Cas9校正模型、ALDH2*2敲入小鼠,发现ALDH2*2导致内皮功能障碍,恩格列净等SGLT2抑制剂可减轻该功能障碍,机制涉及抑制NHE-1并激活AKT/eNOS通路。
要点
- ALDH2*2是CAD最强相关单核苷酸多态性之一。
- 携带ALDH2*2者少量饮酒后血管舒张功能受损。
- 恩格列净减轻ALDH2*2相关内皮功能障碍及小鼠血管功能障碍。
核心结论
- ALDH2*2诱导内皮细胞功能障碍,SGLT2i或可作为ALDH2*2携带者预防CAD的潜在措施。
研究设计与样本
- 研究整合日本生物样本库大规模全基因组关联研究、携带者临床内皮功能评估、人诱导多能干细胞来源内皮细胞(iPSC-ECs)及CRISPR-Cas9校正的ALDH2*2 iPSC-ECs体外模型、ALDH2*2敲入小鼠体内实验。
主要发现
- 在日本生物样本库GWAS中,ALDH2*2是与CAD相关的最强单核苷酸多态性之一。
- 携带ALDH2*2的人参与者少量饮酒后血管舒张功能受损。
- ALDH2*2 iPSC-ECs显示氧化应激和炎症标志物增加、一氧化氮(NO)生成和成管能力下降,乙醇暴露进一步加重。
- 恩格列净等SGLT2i减轻ALDH2*2相关内皮细胞功能障碍。
- 在ALDH2*2敲入小鼠中,恩格列净减轻ALDH2*2介导的血管功能障碍。
临床怎么用
- 原文结论提示SGLT2i或可作为ALDH2*2携带者预防CAD的潜在措施,原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The common aldehyde dehydrogenase 2 (ALDH2) alcohol flushing variant known as ALDH2*2 affects ∼8% of the world's population. Even in heterozygous carriers, this missense variant leads to a severe loss of ALDH2 enzymatic activity and has been linked to an increased risk of coronary artery disease (CAD). Endothelial cell (EC) dysfunction plays a determining role in all stages of CAD pathogenesis, including early-onset CAD. However, the contribution of ALDH2*2 to EC dysfunction and its relation to CAD are not fully understood. In a large genome-wide association study (GWAS) from Biobank Japan, ALDH2*2 was found to be one of the strongest single-nucleotide polymorphisms associated with CAD. Clinical assessment of endothelial function showed that human participants carrying ALDH2*2 exhibited impaired vasodilation after light alcohol drinking. Using human induced pluripotent stem cell-derived ECs (iPSC-ECs) and CRISPR-Cas9-corrected ALDH2*2 iPSC-ECs, we modeled ALDH2*2-induced EC dysfunction in vitro, demonstrating an increase in oxidative stress and inflammatory markers and a decrease in nitric oxide (NO) production and tube formation capacity, which was further exacerbated by ethanol exposure. We subsequently found that sodium-glucose cotransporter 2 inhibitors (SGLT2i) such as empagliflozin mitigated ALDH2*2-associated EC dysfunction. Studies in ALDH2*2 knock-in mice further demonstrated that empagliflozin attenuated ALDH2*2-mediated vascular dysfunction in vivo. Mechanistically, empagliflozin inhibited Na+/H+-exchanger 1 (NHE-1) and activated AKT kinase and endothelial NO synthase (eNOS) pathways to ameliorate ALDH2*2-induced EC dysfunction. Together, our results suggest that ALDH2*2 induces EC dysfunction and that SGLT2i may potentially be used as a preventative measure against CAD for ALDH2*2 carriers.
引用
- Guo H, Yu X, Liu Y, et al. SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant. Sci Transl Med. 2023. PMID: 36696485. doi:10.1126/scitranslmed.abp9952
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。